Net profit of Glaxosmithkline Pharmaceuticals rose 16.09% to Rs 252.50 crore in the quarter ended September 2024 as against Rs 217.51 crore during the previous quarter ended September 2023. Sales rose 5.62% to Rs 1010.77 crore in the quarter ended September 2024 as against Rs 956.99 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1010.77956.99 6 OPM %31.8330.25 - PBDT355.98317.27 12 PBT339.12299.16 13 NP252.50217.51 16 Powered by Capital Market - Live News

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 29 October 2024, has recommended a Special Interim dividend of Rs.12 per share (i.e.120%), subject to the approval of the shareholders.Powered by Capital Market - Live News

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live News

Net profit of Glaxosmithkline Pharmaceuticals rose 37.87% to Rs 182.33 crore in the quarter ended June 2024 as against Rs 132.25 crore during the previous quarter ended June 2023. Sales rose 6.96% to Rs 814.65 crore in the quarter ended June 2024 as against Rs 761.66 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales814.65761.66 7 OPM %28.3018.89 - PBDT265.81180.04 48 PBT249.40163.68 52 NP182.33132.25 38 Powered by Capital Market - Live News

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live News